Ho, Minh
Nguyen, Huynh-Nga
Van Hoang, Minh
Bui, Tien Thuy Thi
Vu, Bao-Quoc
Dinh, Truc Huong Thi
Vo, Hoa Thi My
Blaydon, Diana C.
Eldirany, Sherif A.
Bunick, Christopher G.
Bui, Chi-Bao
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR070290)
Vietnam National University Ho Chi Minh city (DS2023-44-01)
Newton Researcher links (Newton.01.9.2014-2016)
Kenichi Arai research fellowship (KIA092018)
Article History
Received: 14 September 2023
Accepted: 1 April 2024
First Online: 16 April 2024
Declarations
:
: Ethics committee/IRB of University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam, gave ethical approval for this work under clinical trial #CL-VN-UMP-0092QD.
: All necessary patient/participant consent has been obtained under clinical trial #CL-VN-UMP-0092QD and the appropriate institutional forms (IRB of University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam) have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
: C.G.B. has served as a consultant for AbbVie, Eli Lilly, LEO Pharma, Novartis, Pfizer, Sanofi-Regeneron, and UCB; and a speaker for and received honoraria from UCB and LEO Pharma. C.G.B. also serves on the Medical and Scientific Advisory Board of the Foundation for Ichthyosis & Related Skin Types (FIRST).